<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12618157
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     03
    </month>
    <day>
     05
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     04
    </month>
    <day>
     16
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2005
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1470-0328
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       110
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2003
       </year>
       <month>
        Feb
       </month>
      </pubdate>
     </journalissue>
     <title>
      BJOG : an international journal of obstetrics and gynaecology
     </title>
     <isoabbreviation>
      BJOG
     </isoabbreviation>
    </journal>
    <articletitle>
     Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
    </articletitle>
    <pagination>
     <medlinepgn>
      139-44
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To evaluate the effect and dose of dalteparin given to pregnant women with acute venous thromboembolism.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      An observational study of pregnant women in Norway.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Delivery and haematological departments in Norway.
     </abstracttext>
     <abstracttext label="POPULATION" nlmcategory="METHODS">
      Twenty women, aged 22-41 years, with acute venous thromboembolism verified by objective means.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Patients were treated with dalteparin from diagnosis until delivery. Treatment was monitored with anti-activated factor Xa (anti-Xa) activity, and the dose was adjusted to achieve target 0.5-1.0 U/mL 2-3 hours post-injection.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Anti-Xa activity and side effects.
     </abstracttext>
     <abstracttext label="RESULT" nlmcategory="RESULTS">
      None of the patients suffered recurrent venous thromboembolism or major bleeding complications. In 9 of 13 women starting with conventional dose of dalteparin (100 iu/kg bd), dose escalation was necessary to reach target anti-Xa activity. None of the six women who started with 105-118 iu/kg bd required dose escalation. One woman who started with 133 iu/kg bd required dose reduction. Bioaccumulation of dalteparin was not observed.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Our study suggests that dalteparin may be used for the treatment of acute venous thromboembolism in pregnancy. Approximately 10-20% higher doses of dalteparin may be needed as compared with non-pregnant individuals.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Obstetrics and Gynaecology, Ullev√•l University Hospital, Oslo, Norway.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Jacobsen
      </lastname>
      <forename>
       Anne Flem
      </forename>
      <initials>
       AF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Qvigstad
      </lastname>
      <forename>
       Erik
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sandset
      </lastname>
      <forename>
       Per Morten
      </forename>
      <initials>
       PM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Evaluation Studies
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     BJOG
    </medlineta>
    <nlmuniqueid>
     100935741
    </nlmuniqueid>
    <issnlinking>
     1470-0328
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anticoagulants
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Dalteparin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 3.4.21.6
     </registrynumber>
     <nameofsubstance>
      Factor Xa
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Acute Disease
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anticoagulants
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dalteparin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Factor Xa
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      Norway
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy Complications, Cardiovascular
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy Outcome
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thromboembolism
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      3
     </month>
     <day>
      6
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      4
     </month>
     <day>
      17
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      3
     </month>
     <day>
      6
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12618157
    </articleid>
    <articleid idtype="pii">
     S1470032802021821
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

